Comparative Pharmacology
Head-to-head clinical analysis: TRIPHASIL 28 versus VOLNEA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIPHASIL 28 versus VOLNEA.
TRIPHASIL-28 vs VOLNEA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin secretion, inhibits ovulation, alters cervical mucus and endometrium.
Volnea is a combination of dienogest and ethinylestradiol. Dienogest is a progestin with antiandrogenic activity, and ethinylestradiol is an estrogen. The contraceptive effect is achieved through suppression of gonadotropins (FSH and LH), inhibition of ovulation, and changes in cervical mucus and endometrium.
1 tablet orally once daily for 28 days; each tablet contains levonorgestrel 0.050 mg and ethinyl estradiol 0.030 mg (6 days), levonorgestrel 0.075 mg and ethinyl estradiol 0.040 mg (5 days), levonorgestrel 0.125 mg and ethinyl estradiol 0.030 mg (10 days), followed by 7 inert tablets. The first dose is taken on the first Sunday after onset of menstruation or on day 1 of the menstrual cycle.
One tablet (0.02 mg ethinylestradiol + 3 mg drospirenone) orally once daily for 21 consecutive days, followed by a 7-day hormone-free interval.
None Documented
None Documented
Levonorgestrel: terminal half-life 11-45 hours (mean 24-30 h); Ethinyl estradiol: terminal half-life 10-27 hours (mean 17 h). Steady-state reached after 5-7 days.
Terminal half-life: 12 hours (range 10-14 h). Supports twice-daily dosing in patients with normal renal function.
Renal (about 50-60% as metabolites, <10% unchanged), fecal (about 30-40% via biliary elimination). Ethinyl estradiol undergoes enterohepatic recirculation.
Renal: 70% unchanged; fecal: 30% (biliary elimination)
Category C
Category C
Oral Contraceptive
Oral Contraceptive